Results 1 to 10 of about 126,792 (189)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
mid- ventricular, and post- SRT phenotypes. Patients with heart failure with preserved ejection fraction also represent a future target for CMIs given their mechanism of action.
Ahmad Masri, Iacopo Olivotto
doaj   +3 more sources

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials [PDF]

Frontiers in Cardiovascular Medicine
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM).
Anas Abunada, Madiha Shah, Ateesh Kumar, Syeda Lamiya Mir, Dinesh Kumar, Saboor Ahmed, Muhammad Tanzeel, Vikash Kumar, Aashish Meghjiani, Muhammad Basit Ali Siddiqui, Govinda Khatri, Aneesh Rai, Fnu Deepak, Ayush Kumar   +13 more
doaj   +3 more sources

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials [PDF]

Open Heart
Background Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman, Arfa Akram, Bisma Akram, Momina Maham, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Furqan Yaqub   +7 more
doaj   +3 more sources

Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort [PDF]

Reviews in Cardiovascular Medicine
Background: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani   +7 more
doaj   +3 more sources

Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy [PDF]

The Egyptian Heart Journal
Background Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of ...
Ikponmwosa Jude Ogieuhi, Victor Oluwatomiwa Ajekiigbe, Boluwaduro Abasiekem Adeyemi, Bright Nwatamole, Komolafe Babajide Ayodeji, Oshomoh Mark-Anthony Ugiomoh, Temiloluwa Adebayo Odeniyi, Adewunmi Akingbola, Efosa Peace Iyawe, Olabode Olawale Oladejo, Motunrayo Oluwatoyosi Lawal, Nathnael Abera Woldehana, Ifeoluwa Sandra Bakare, Adejumo Temilade Patience, Grace Chinenye Okoro   +14 more
doaj   +3 more sources

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]

Int J Mol Sci
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes.
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.   +7 more
europepmc   +2 more sources

Cardiac myosin inhibitors in hypertrophic cardiomyopathy. [PDF]

J Cardiovasc Imaging
Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM).
Lim J, Kim HK.
europepmc   +2 more sources

Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges [PDF]

Biomolecules
Hypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Arnold Kukowka, Marek Droździk
doaj   +2 more sources

Cardiac myosin inhibitors for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Background/objective: HCM is a structural disorder of the myocardium that leads to sudden cardiac death in young adults. We synthesized an updated understanding of the role of Cardiac Myosin Inhibitors (CMIs) in HCM by pooling data from RCTs. Methods: We
Hasana U, Korpal M, Haider F, Umer M, Lwin NPT, Iqbal S, Kumar R, Ahsan M, Hassan E, Ullah W, Khalid S, Gupta A, Alsubari AMA, Ehsan M, Ahmad A.   +14 more
europepmc   +2 more sources

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy

Scientific Reports, 2023
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease in humans and cats and lacks efficacious pharmacologic interventions in the preclinical phase of disease.
Ashley N. Sharpe, Maureen S. Oldach, Victor N. Rivas, Joanna L. Kaplan, Ashley L. Walker, Samantha L. Kovacs, Darren T. Hwee, Peadar Cremin, Bradley P. Morgan, Fady I. Malik, Samantha P. Harris, Joshua A. Stern   +11 more
doaj   +2 more sources